论文信息 - Second-line afatinib vs erlotinib for patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8 [LL8]): analysis of tumour and serum biomarkers and long-term responders - 字舞流文

Second-line afatinib vs erlotinib for patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8 [LL8]): analysis of tumour and serum biomarkers and long-term responders

K. Syrigos | E. Felip | J. Soria | A. Ardizzoni | N. Gibson | S. Gadgeel | Wei Li | E. Göker | E. Ehrnrooth | G. Goss | F. Solca | Shun Lu | K. Lee | M. Cobo | D. Isla | V. Georgoulias | N. Dupuis | S. Guclu | C. Bühnemann | N. Krämer